	US 12,280,045 B2
	Antitumor agent and antitumor effect potentiator
Tomonori Haruma, Ibaraki (JP)
Assigned to TAIHO PHARMACEUTICAL CO., LTD., Tokyo (JP)
Appl. No. 16/645,315
Filed by TAIHO PHARMACEUTICAL CO., LTD., Chiyoda-ku (JP)
PCT Filed Sep. 6, 2018, PCT No. PCT/JP2018/033108 § 371(c)(1), (2) Date Mar. 6, 2020, PCT Pub. No. WO2019/049956, PCT Pub. Date Mar. 14, 2019.
Claims priority of application No. 2017-173352 (JP), filed on Sep. 8, 2017.
Prior Publication US 2021/0030738 A1, Feb. 4, 2021
Int. Cl. A61K 31/47 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/47 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01)]

4 Claims

1. A method of treating a malignant tumor selected from the group consisting of melanoma, kidney cancer, lung cancer, head and neck cancer, Hodgkin's lymphoma, bladder cancer, colon cancer, liver cancer, stomach cancer, osteosarcoma and soft tissue sarcoma, breast cancer, and prostate cancer comprising coadministration 4-(2-fluoro-4-(3-(2-phenylacetyl) thioureido) phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a salt thereof, and an immune checkpoint molecule regulator comprising an anti-PD-1 antibody.